Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Sutro Biopharma, Inc.NASDAQ: STRO

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$294.17, compared with -$9.1 a year earlier. Trailing-twelve-month EPS (Basic) was -$307.72.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$8.12 (+63.9%) for the fiscal year ending Dec 2026, a step up from the +24.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$294.17-5297.6% QoQ
Last fiscal yearDec 2025
-$22.49+24.0% YoY
LTMMar 2026
-$307.72-936.1% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3132.6%-56.7%+3075.9 pp
1 year+24.0%+63.9%+39.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(22.49) USD
Year-over-year change
+24.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -936.1% is the lowest of 9, against a peer median of +12.0%.
STRO Competitors
EPS (Basic) for STRO and competitors
Company Period LTM YoY 3-year CAGR
IFRXInflaRx N.V.LTM Mar 2026-€0.61 EUR+18.5%—
STTKShattuck Labs, Inc.LTM Mar 2026-$0.63 USD+54.7%—
CNTBConnect Biopharma Holdings LimitedFY2025-$1 USD-257.1%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$1.74 USD+5.4%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$1.84 USD+49.0%—
KLRSKalaris Therapeutics IncLTM Mar 2026-$2.15 USD+85.6%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$3.55 USD-11.3%—
DTILPrecision BioSciences, Inc.LTM Mar 2026-$4.35 USD-84.3%—
STROSutro Biopharma, Inc.LTM Mar 2026-$307.72 USD-936.1%—
Peer median (excluding STRO) —+12.0%—

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.